Tanya Dorff, MD

GU Oncology Now

<p>Tanya Dorff, MD, Associate Professor in the Department of Medical Oncology &amp; Therapeutics Research, and Section Chief of the Genitourinary Disease Program, City of Hope Comprehensive Cancer Center, shares the barriers to utilizing PARP inhibitors plus androgen receptor-targeted agents in the castration-sensitive or upfront prostate cancer settings.<p>View Dr. Dorff&rsquo;s other comments on treatment for prostate cancer, including <a href="https://guoncologynow.com/post/propel-and-magnitude-trials-for-mcrpc" target="_blank" rel="noopener">PROpel and MAGNITUDE Trials for mCRPC</a> and <a href="https://guoncologynow.com/post/combination-versus-sequential-therapy-for-mcrpc" target="_blank" rel="noopener">Combination Versus Sequential Therapy for mCRPC</a>.</p></p>


Barriers to PARP Inhibitors Plus Androgen Receptor-Targeted Agents in Earlier Treatment Settings

mCSPC

Tanya Dorff, MD, shares the barriers to utilizing PARP inhibitors plus AR-targeted agents in the castration-sensitive or upfront prostate cancer settings.

Barriers to PARP Inhibitors Plus AR-Targeted Agents in Earlier Settings

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe